Segments

The BRAINBiocatalysts segment comprises the product business with specialized enzymes, microorganisms and ingredients. The BRAIN Biotech Group operates fermentation facilities in the United Kingdom and production facilities in Continental Europe and the United States.

The legal entity for the product business is the wholly owned subsidiary Biocatalysts Ltd. in Cardiff, Wales, United Kingdom.

The R&D activities at the Zwingenberg site contribute to the development of innovative products and the expansion of the product portfolio. Customer-specific developments of enzymes, strains and bioprocesses for industrial applications are also initially developed there and then transferred to the Cardiff site for upscaling.

The BRAINBioIncubator segment comprises research-intensive, customer-specific solutions based on enzyme technology, strain development, bioprocess development and natural product screening.

This segment also includes partnered projects with high value creation potential (innovation pipeline).

Examples:

• In-house development of proprietary CRISPR-Cas nucleases for genome editing in customer projects
• Aurase® enzyme for wound healing: successful completion of the Phase 2a clinical trial by partner SolasCure
• Biological gold recovery from e-waste: further development by an industrial partner.
• Identification and characterization of an active substance for the treatment of hereditary angioedema (HAE): out-licensing and clinical development by Pharvaris N.V.